Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 16/20 | 0.43 |
| ▸ | CDC7 | O00311 | 1/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.41 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6477607 | 0.94 | HDAC1 (0.42) | KMT2AMAPK1ALDH1A1PARP1 | |
| SCHEMBL6470445 | 0.93 | CDC7 (0.46) | KMT2AMAPK1CDC7ROCK2MAP4K4 | |
| SCHEMBL6467963 | 0.90 | LMNA (0.42) | KMT2AMAPK1ALDH1A1PARP1 | |
| SCHEMBL6470160 | 0.90 | HDAC1 (0.43) | KMT2AMAPK1PARP1 | |
| SCHEMBL6467560 | 0.89 | ROCK1 (0.46) | KMT2AROCK2GSK3BCLK4ALDH1A1 | |
| SCHEMBL6504083 | 0.88 | AXL (0.41) | KMT2AMAPK1ALDH1A1PARP1 | |
| SCHEMBL6470232 | 0.87 | ALOX5AP (0.41) | MAPK1ALDH1A1PARP1 | |
| SCHEMBL6506262 | 0.86 | MAPK1 (0.51) | KMT2AMAPK1ROCK2MAP4K4GSK3B | |
| SCHEMBL6504428 | 0.86 | PDE10A (0.44) | KMT2AROCK2ALDH1A1 | |
| SCHEMBL6467616 | 0.85 | KIF11 (0.43) | MAPK1ALDH1A1PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050197338-A1 | Substituted pyrazole urea compounds for the treatment of inflammation | PHARMACIA AND UPJOHN COMPANY LLC | 2005-09-08 | — | — | US | disclosed |
| WO-2005037797-A1 | SUBSTITUTED PYRAZOLE UREA COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | PHARMACIA CORPORATION (US) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197338-A1 | Substituted pyrazole urea compounds for the treatment of inflammation | IL4, ARG2, CASP4 | KMT2A 3219/4885MAPK1 1770/4885CDC7 3112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.